Clinical trial
A Phase 3, Single-arm, 12-week Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Indian Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
NCT07829653 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Single-arm, 12-week Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Indian Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- April 30, 2028
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.